OptiNose (OPTN) Competitors $5.30 -0.36 (-6.36%) As of 01/10/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends OPTN vs. URGN, ACB, LRMR, GOSS, LFCR, LXEO, INBX, CRDF, DMAC, and ZNTLShould you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include UroGen Pharma (URGN), Aurora Cannabis (ACB), Larimar Therapeutics (LRMR), Gossamer Bio (GOSS), Lifecore Biomedical (LFCR), Lexeo Therapeutics (LXEO), Inhibrx (INBX), Cardiff Oncology (CRDF), DiaMedica Therapeutics (DMAC), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. OptiNose vs. UroGen Pharma Aurora Cannabis Larimar Therapeutics Gossamer Bio Lifecore Biomedical Lexeo Therapeutics Inhibrx Cardiff Oncology DiaMedica Therapeutics Zentalis Pharmaceuticals UroGen Pharma (NASDAQ:URGN) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability, community ranking and media sentiment. Does the MarketBeat Community prefer URGN or OPTN? UroGen Pharma received 117 more outperform votes than OptiNose when rated by MarketBeat users. Likewise, 73.89% of users gave UroGen Pharma an outperform vote while only 63.59% of users gave OptiNose an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes36573.89% Underperform Votes12926.11% OptiNoseOutperform Votes24863.59% Underperform Votes14236.41% Which has more volatility & risk, URGN or OPTN? UroGen Pharma has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500. Is URGN or OPTN more profitable? OptiNose has a net margin of -41.16% compared to UroGen Pharma's net margin of -129.11%. Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% OptiNose -41.16%N/A -27.42% Does the media refer more to URGN or OPTN? In the previous week, OptiNose had 2 more articles in the media than UroGen Pharma. MarketBeat recorded 4 mentions for OptiNose and 2 mentions for UroGen Pharma. OptiNose's average media sentiment score of 1.31 beat UroGen Pharma's score of 1.26 indicating that OptiNose is being referred to more favorably in the news media. Company Overall Sentiment UroGen Pharma Positive OptiNose Positive Do insiders and institutionals hold more shares of URGN or OPTN? 91.3% of UroGen Pharma shares are held by institutional investors. Comparatively, 85.6% of OptiNose shares are held by institutional investors. 5.1% of UroGen Pharma shares are held by company insiders. Comparatively, 2.3% of OptiNose shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, URGN or OPTN? OptiNose has lower revenue, but higher earnings than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$89.36M2.69-$102.24M-$3.15-3.25OptiNose$75.67M0.70-$35.48M-$4.20-1.26 Do analysts rate URGN or OPTN? UroGen Pharma currently has a consensus price target of $43.70, indicating a potential upside of 326.76%. OptiNose has a consensus price target of $26.00, indicating a potential upside of 390.57%. Given OptiNose's higher possible upside, analysts plainly believe OptiNose is more favorable than UroGen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17OptiNose 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryUroGen Pharma beats OptiNose on 12 of the 18 factors compared between the two stocks. Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPTN vs. The Competition Export to ExcelMetricOptiNosePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.32M$6.63B$5.27B$8.85BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-18.9310.2986.7116.80Price / Sales0.70193.181,094.44118.41Price / CashN/A57.6943.2437.77Price / Book-6.884.975.104.93Net Income-$35.48M$153.69M$122.02M$227.55M7 Day Performance-13.40%-5.83%-3.40%-4.04%1 Month Performance-24.98%-0.33%0.48%0.77%1 Year Performance-72.18%-2.00%24.99%14.84% OptiNose Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTNOptiNose4.3194 of 5 stars$5.30-6.4%$26.00+390.6%-72.2%$53.32M$75.67M-18.93190Positive NewsURGNUroGen Pharma3.8537 of 5 stars$11.21flat$43.70+289.8%-29.8%$262.92M$89.36M-3.56200Positive NewsACBAurora Cannabis0.5634 of 5 stars$4.67-0.6%N/A-9.8%$256.12M$296.99M-6.141,073Positive NewsLRMRLarimar Therapeutics1.8951 of 5 stars$4.01-4.1%$20.43+409.4%-20.6%$255.87MN/A-3.4930Positive NewsGOSSGossamer Bio4.0514 of 5 stars$1.11+8.8%$9.20+728.8%-0.2%$251.53M$105.32M-3.47180Positive NewsGap DownLFCRLifecore Biomedical3.2192 of 5 stars$6.81-10.6%$8.00+17.5%-8.4%$250.79M$128.44M85.13690Analyst RevisionLXEOLexeo Therapeutics3.1984 of 5 stars$7.31+0.3%$23.80+225.6%-59.1%$241.71M$650,000.00-2.3158INBXInhibrx1.2569 of 5 stars$16.39+1.5%N/A-59.3%$237.26M$1.57M0.00166CRDFCardiff Oncology2.558 of 5 stars$4.61-1.9%$10.33+124.2%+113.6%$235.73M$688,000.00-4.9020Positive NewsDMACDiaMedica Therapeutics1.8243 of 5 stars$5.47-1.6%$7.00+28.0%+76.3%$233.90MN/A-9.7720News CoverageZNTLZentalis Pharmaceuticals1.3905 of 5 stars$3.21-0.9%$10.00+211.5%-80.7%$228.76M$40.56M-1.29160 Related Companies and Tools Related Companies UroGen Pharma Alternatives Aurora Cannabis Alternatives Larimar Therapeutics Alternatives Gossamer Bio Alternatives Lifecore Biomedical Alternatives Lexeo Therapeutics Alternatives Inhibrx Alternatives Cardiff Oncology Alternatives DiaMedica Therapeutics Alternatives Zentalis Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPTN) was last updated on 1/13/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
